Structure Therapeutics INC

Structure Therapeutics reported Q2 2026 financial results, highlighted by the initiation of Phase 3 trials for its oral GLP-1 agonist aleniglipron and a robust cash reserve extending runway through 2028.

Structure Therapeutics Inc. has amended its sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. to remove the aggregate offering amount for its at-the-market (ATM) shares, while also filing a prospectus supplement to increase the aggregate offering price to $400 million.

Structure Therapeutics Inc. announced the appointment of Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026, bringing extensive executive leadership experience in the biopharmaceutical sector.

Structure Therapeutics announced positive topline data from its Phase 2 ACCESS II trial and interim data from supplementary studies for its oral GLP-1 receptor agonist, aleniglipron, demonstrating significant weight loss and improved tolerability.

Structure Therapeutics announced positive Phase 2 aleniglipron data, a robust cash position, and plans for Phase 3 initiation in 2H 2026.

Structure Therapeutics' subsidiary, Gasherbrum Bio, entered a non-exclusive licensing agreement with Genentech and Roche for certain GLP-1 receptor agonist patents, securing a $100 million upfront payment and future royalties.

Structure Therapeutics Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing increased R&D expenses and a substantial net loss, while highlighting progress in its clinical pipeline.

Structure Therapeutics Inc. reported increased R&D expenses and a wider net loss for Q1 2026, while maintaining a strong cash position.

Structure Therapeutics reports increased net losses in Q3 2025, driven by higher R&D, while advancing its obesity and IPF clinical programs and securing additional capital.

Structure Therapeutics reported significantly increased net losses in Q2 2025 driven by a substantial rise in research and development expenses as it advances its oral small molecule pipeline.

Structure Therapeutics reports a net loss of $46.8 million for Q1 2025, while advancing its clinical programs, including aleniglipron and LTSE-2578.

Structure Therapeutics reports positive topline data from its Phase 2a obesity study of GSBR-1290, showing a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks, and initiates a Phase 2b trial.

Structure Therapeutics Inc. reports significant progress in its obesity and metabolic disease pipeline, including positive Phase 2b data for aleniglipron and a $100 million non-exclusive license agreement.

Structure Therapeutics Inc. announces its 2024 financial results and highlights progress in its clinical programs targeting obesity and idiopathic pulmonary fibrosis (IPF).

Structure Therapeutics Inc.'s annual 10-K filing highlights advancements in their clinical programs, particularly for GSBR-1290, and strategic collaborations with Schrdinger.

Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 3,939 shares of common stock on August 18, 2026.

John Joseph Berrios, Chief Commercial Officer of Structure Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 3,939 shares of common stock on August 4, 2026.

Fmr Llc reported changes in beneficial ownership of Structure Therapeutics Inc. common stock on July 22, 2026.

Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 7,878 shares of common stock on July 14, 2026.

Structure Therapeutics Chief Scientific Officer Lin Xichen reported a transaction involving the sale of American Depositary Shares acquired through an option exercise, as part of a Rule 10b5-1 trading plan.

Structure Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for the upcoming annual general meeting of shareholders on June 17, 2026.

Structure Therapeutics will hold its 2025 Annual General Meeting virtually on June 23, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.

Structure Therapeutics will hold its 2024 Annual General Meeting of Shareholders virtually on June 25, 2024, to vote on the election of a director and ratification of the company's independent auditor.

Structure Therapeutics has filed a registration statement to increase the aggregate offering price of its American Depositary Shares (ADSs) by $64.4 million.

Structure Therapeutics is launching a public offering of American Depositary Shares and pre-funded warrants to fuel its clinical programs.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 13.2% in Structure Therapeutics Inc. as of June 30, 2026.

Deep Track Capital and its affiliates have disclosed a 5.95% beneficial ownership stake in Structure Therapeutics Inc., holding 12,335,346 ordinary shares.

Wellington Management Group LLP and its affiliates have reported a 10.1% beneficial ownership stake in Structure Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, reporting a beneficial ownership of 15.0% of Structure Therapeutics Inc.'s common stock as of December 31, 2025.

Janus Henderson Group plc reports an increased beneficial ownership of 7.7% in Structure Therapeutics Inc. through American Depositary Shares.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 9.38% beneficial ownership stake in Structure Therapeutics Inc. as of September 30, 2025.